首页 | 本学科首页   官方微博 | 高级检索  
     

肿瘤坏死因子拮抗剂治疗强直性脊柱炎伴发葡萄膜炎的临床疗效评价
引用本文:宋国祥 黄进贤 尹志华 邓亚玲 梁张翼 叶志中. 肿瘤坏死因子拮抗剂治疗强直性脊柱炎伴发葡萄膜炎的临床疗效评价[J]. 现代生物医学进展, 2015, 15(4): 661-663
作者姓名:宋国祥 黄进贤 尹志华 邓亚玲 梁张翼 叶志中
作者单位:深圳市第三人民医院眼科;广东医学院附属福田医院香蜜湖风湿病分院;广东医学院风湿病研究所
基金项目:国家自然基金项目青年科学基金项目(81301529);广东省自然科学基金博士启动项目(S2013040012296);深圳市福田区卫生公益性科研项目(FTWS201308)
摘    要:目的:探讨肿瘤坏死因子拮抗剂治疗强直性脊柱炎(AS)伴发葡萄膜炎的临床效果和安全性。方法:将2011年6月~2013年6月我院收治的80例AS伴发葡萄膜炎的患者随机分为研究组和对照组。研究组患者给予肿瘤坏死因子拮抗剂皮下注射25 mg,每周2次,甲氨蝶呤10 mg口服,每周一次,同时眼科局部用药;对照组患者给予柳氮磺吡啶片0.75 g,每日3次口服,甲氨蝶呤10 mg口服,每周一次,同时局部眼科局部用药(剂量、疗程同前),治疗12周。观察和比较两组患者治疗前后眼部情况、ESR、CRP、BASDAI、BASFI评分改善情况。结果:治疗后,两组患者各项指标较治疗前比较均显著改善(P均0.05);研究组的改善程度与对照组相比无显著差异(P0.05),但研究组葡萄膜炎病程较对照组显著缩短(P0.05)。治疗过程中,两组患者均未发生严重不良反应。结论:肿瘤坏死因子拮抗剂和甲氨蝶呤联合眼科局部治疗AS伴发葡萄膜炎疗效显著,能缩短葡萄膜炎病程,耐受性和安全性良好。

关 键 词:强直性脊柱炎  葡萄膜炎  肿瘤坏死因子拮抗剂  临床疗效

Evaluation of the Therapeutic Effect of Tumor Necrosis Factor Inhibitor inthe Treatment of Ankylosing Spondylitis Combined with Uveitis
SONG Guo-xiang;HUANG Jin-xian;YIN Zhi-hua;DENG Ya-ling;LIANG Zhang-yi;YE Zhi-zhong. Evaluation of the Therapeutic Effect of Tumor Necrosis Factor Inhibitor inthe Treatment of Ankylosing Spondylitis Combined with Uveitis[J]. Progress in Modern Biomedicine, 2015, 15(4): 661-663
Authors:SONG Guo-xiang  HUANG Jin-xian  YIN Zhi-hua  DENG Ya-ling  LIANG Zhang-yi  YE Zhi-zhong
Affiliation:SONG Guo-xiang;HUANG Jin-xian;YIN Zhi-hua;DENG Ya-ling;LIANG Zhang-yi;YE Zhi-zhong;Department of Ophthalmology, The Third People’s Hospital of Shenzhen City;Department of Rheumatology, The Affiliated Futian Hospital of Guangdong Medical College, Rheumatology Institute of Guangdong Medical College;
Abstract:Objective:To investigate the therapeutic effect and safety of tumor necrosis factor inhibitor in the treatment of ankylosingspondylitis (AS) associated with uveitis.Methods:Eighty patients with uveitis associated with AS hospitalized from June 2011 toJune 2013 were randomly divided into the observation group and control group. Forty cases in the observation group received subcutaneouslyinjection of tumor necrosis factor inhibitor 25mg twice per week, in combination with oral methotrexate 10mg per week andophthalmologic local application for 12 weeks. Forty cases in the control group received oral sulfasalazine 750mg three times per day, incombination with oral methotrexate and ophthalmologic local application with the same dosage and course. The ocular condition, ESR,CRP, BASDAI and BASFI index were evaluated and compared before and after treatment between two groups.Results:The assessmentindexes were significantly improved in both groups after treatment (P<0.05). The improvement was not significant between observationgroup and control group (P>0.05), while uveitis course was significantly shorter in observation group than that in control group (P<0.05).During the treatment process, no severe adverse event happened in both groups.Conclusion:Tumor necrosis factor inhibitor in combinationwith methotrexate and ophthalmologic local application treatment had prominent effect, which could shorten the uveitis course andwas well tolerable and safe.
Keywords:Ankylosing spondylitis  Uveitis  Tumor necrosis factor inhibitor  Clinical efficacy
本文献已被 CNKI 万方数据 等数据库收录!
点击此处可从《现代生物医学进展》浏览原始摘要信息
点击此处可从《现代生物医学进展》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号